文献速递脑血管病

轻型卒中溶栓:PRISMS与MaRISS研究的比较分析

Thrombolysis in Mild Stroke: A Comparative Analysis of the PRISMS and MaRISS Studies.
PubMed 文献 · Stroke · 2021-09-09

本研究比较了PRISMS随机对照试验入组的轻型缺血性卒中患者与MaRISS前瞻性登记研究中NIHSS≤5患者的基线严重程度分布。结果显示,PRISMS患者的神经功能缺损和症候严重程度与MaRISS中未接受阿替普酶治疗者相当,而轻于MaRISS中接受阿替普酶治疗者,提示PRISMS试验队列可代表当前广泛临床实践中未接受溶栓的轻型卒中患者。

要点

  • PRISMS试验入组患者的神经功能缺损严重程度与MaRISS登记中未溶栓的轻型卒中患者相当。
  • MaRISS中接受阿替普酶治疗的患者基线严重程度高于PRISMS随机入组者。
  • 解读轻型卒中溶栓证据时需注意试验人群与实际临床人群的严重程度差异。

核心结论

  • PRISMS随机入组患者的缺损与症候严重程度与MaRISS登记中未接受阿替普酶治疗者相当,且轻于MaRISS中接受阿替普酶治疗者。
  • PRISMS试验队列可代表当前广泛临床实践中未接受阿替普酶的轻型卒中患者。

研究设计与样本

  • 比较PRISMS随机对照试验入组患者与MaRISS前瞻性登记研究中NIHSS评分≤5患者的NIHSS评分分布及神经症状/严重程度。
  • MaRISS共纳入1736例参与者,其中972例(56%)接受阿替普酶治疗,764例(44%)未接受;对照组为PRISMS随机入组的313例患者。
  • 采用χ2分析的全局P值进行组间比较。

主要发现

  • NIHSS评分中位数在MaRISS阿替普酶治疗组为3(2–4),MaRISS未溶栓组为1(1–3),PRISMS组为2(1–3)。
  • NIHSS评分0至2分的比例在三组分别为36.3%、73.3%和65.2%(P<0.0001)。
  • 存在优势神经症候(至少1项NIHSS条目评分≥2)的比例在MaRISS阿替普酶治疗组为32%,MaRISS未溶栓组为13.8%,PRISMS组为8.6%(P<0.0001)。

临床怎么用

  • 解读轻型卒中溶栓随机试验结果时,应考虑试验入组人群与真实临床人群在基线严重程度上的分布差异。
  • PRISMS结果外推至临床实践中未溶栓的轻型卒中患者时具有一定代表性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Mild ischemic stroke patients enrolled in randomized controlled trials of thrombolysis may have a different symptom severity distribution than those treated in routine clinical practice. METHODS: We compared the distribution of the National Institutes of Health Stroke Scale (NIHSS) scores, neurological symptoms/severity among patients enrolled in the PRISMS (Potential of r-tPA for Ischemic Strokes With Mild Symptoms) randomized controlled trial to those with NIHSS score ≤5 enrolled in the prospective MaRISS (Mild and Rapidly Improving Stroke Study) registry using global P values from χ2 analyses. RESULTS: Among 1736 participants in MaRISS, 972 (56%) were treated with alteplase and 764 (44%) were not. These participants were compared with 313 patients randomized in PRISMS. The median NIHSS scores were 3 (2–4) in MaRISS alteplase-treated, 1 (1–3) in MaRISS non–alteplase-treated, and 2 (1–3) in PRISMS. The percentage with an NIHSS score of 0 to 2 was 36.3%, 73.3%, and 65.2% in the 3 groups, respectively (P<0.0001). The proportion of patients with a dominant neurological syndrome (≥1 NIHSS item score of ≥2) was higher in MaRISS alteplase-treated (32%) compared with MaRISS nonalteplase-treated (13.8%) and PRISMS (8.6%; P<0.0001). CONCLUSIONS: Patients randomized in PRISMS had comparable deficit and syndromic severity to patients not treated with alteplase in the MaRISS registry and lesser severity than patients treated with alteplase in MaRISS. The PRISMS trial cohort is representative of mild patients who do not receive alteplase in current broad clinical practice.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Asdaghi N, Romano JG, Gardener H, et al. Thrombolysis in Mild Stroke: A Comparative Analysis of the PRISMS and MaRISS Studies. Stroke. 2021. PMID: 34496619. doi:10.1161/STROKEAHA.120.033466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。